The long range goal of this proposal is to improve the efficacy and utility of inhaled nitric oxide as a selective pulmonary vasodilator in cardiopulmonary disease. In addition to relaxing tone in the pulmonary circulation, NO alternates platelet aggregation and scavenge superoxide radicals. The applicant also plans to investigate whether NO exerts its beneficial effects by the cGMP signal transduction pathway. A variety of relevant and important techniques will be employed, including endothelial, neuronal and inducible NOS knockout mice, complement activation, signal transduction pathway analysis, and application of inhaled NO to thrombin-induced, hyperoxic, and complement mediated forms of lung injury. There are 3 specific aims:
Specific Aim 1 will investigate the basis for the lack of response to inhaled NO in 35% of the patients given this treatment. The applicant plans to investigate the NO-cGMP signal transduction pathway, role of phosphodiesterase (PDE) activity, influence of endotoxin, feedback inhalation of NO on NOS activity and induction of tachyphylaxis, and compare several of these mechanisms in rats to sheep.
Specific Aim 2 is to investigate the interactions of inhaled NO with intrapulmonary NOS activity. This involves studying the three isoforms of NOS and whether absence of any one form via knockout mice alters the response to inhaled NO and to bacterial endotoxin. The applicant also plans to study exhaled NO as a marker of pulmonary NOS activity in each NOS deficient knockout mouse.
Specific Aim 3 is to determine how both endogenously released and exogeneously administered NO influences the resonse of the injured lung. Three forms of lung injury will be used (i.e., hyperoxia, thrombin, and complement activation).

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL042397-10
Application #
6030588
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1990-07-01
Project End
2000-06-30
Budget Start
1999-07-01
Budget End
2000-06-30
Support Year
10
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Vaporidi, Katerina; Vergadi, Eleni; Kaniaris, Evangelos et al. (2012) Pulmonary microRNA profiling in a mouse model of ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 303:L199-207
Steinbicker, Andrea U; Liu, Heling; Jiramongkolchai, Kim et al. (2011) Nitric oxide regulates pulmonary vascular smooth muscle cell expression of the inducible cAMP early repressor gene. Nitric Oxide 25:294-302
Petersen, Bodil; Austen, K Frank; Bloch, Kenneth D et al. (2011) Cysteinyl leukotrienes impair hypoxic pulmonary vasoconstriction in endotoxemic mice. Anesthesiology 115:804-11
Yu, Binglan; Shahid, Mohd; Egorina, Elena M et al. (2010) Endothelial dysfunction enhances vasoconstriction due to scavenging of nitric oxide by a hemoglobin-based oxygen carrier. Anesthesiology 112:586-94
Vaporidi, Katerina; Francis, Roland C; Bloch, Kenneth D et al. (2010) Nitric oxide synthase 3 contributes to ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol 299:L150-9
Buys, Emmanuel S; Cauwels, Anje; Raher, Michael J et al. (2009) sGC(alpha)1(beta)1 attenuates cardiac dysfunction and mortality in murine inflammatory shock models. Am J Physiol Heart Circ Physiol 297:H654-63
Yu, Binglan; Volpato, Gian Paolo; Chang, Keqin et al. (2009) Prevention of the pulmonary vasoconstrictor effects of HBOC-201 in awake lambs by continuously breathing nitric oxide. Anesthesiology 110:113-22
Yu, Binglan; Bloch, Kenneth D; Zapol, Warren M (2009) Hemoglobin-based red blood cell substitutes and nitric oxide. Trends Cardiovasc Med 19:103-7
Petersen, Bodil; Bloch, Kenneth D; Ichinose, Fumito et al. (2008) Activation of Toll-like receptor 2 impairs hypoxic pulmonary vasoconstriction in mice. Am J Physiol Lung Cell Mol Physiol 294:L300-8
Yu, Binglan; Raher, Michael J; Volpato, Gian Paolo et al. (2008) Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 117:1982-90

Showing the most recent 10 out of 104 publications